HLS Therapeutics Investor Presentation 2021

Loading viewer...

investor_presentation

Format: PDF investor_presentation

HLS Therapeutics presents its 2021 investor update highlighting Vascepa as an inflection point for growth. The company projects peak-year Vascepa royalty revenue of C$275-325M and C$100-130M in other revenue, with estimated market cap of C$540M. Key products include Clozaril, Trinomia, PERSERIS, and MyCare.

Browse all investor_presentations →

Related tags

Your message matters.

Let us design a presentation that delivers.

Lets get started

More from HLS Therapeutics Inc.

View all →

HLS Therapeutics 2018 Spring Investor Presentation

investor_presentation

24 Pages

HLS Therapeutics Inc. Investor Presentation November 2023

investor_presentation

Similar investor_presentations from other companies

Browse all →

Vanda Pharmaceuticals 2017 Corporate Presentation

investor_presentation

32 Pages

Vanda Pharmaceuticals

Valmet Roadshow Presentation April 2021

investor_presentation